GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (XTER:SRT) » Definitions » EV-to-Revenue

Sartorius AG (XTER:SRT) EV-to-Revenue : 6.46 (As of May. 05, 2024)


View and export this data going back to 1990. Start your Free Trial

What is Sartorius AG EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Sartorius AG's enterprise value is €21,407 Mil. Sartorius AG's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €3,312 Mil. Therefore, Sartorius AG's EV-to-Revenue for today is 6.46.

The historical rank and industry rank for Sartorius AG's EV-to-Revenue or its related term are showing as below:

XTER:SRT' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.92   Med: 5.69   Max: 19.07
Current: 6.46

During the past 13 years, the highest EV-to-Revenue of Sartorius AG was 19.07. The lowest was 1.92. And the median was 5.69.

XTER:SRT's EV-to-Revenue is ranked worse than
73.21% of 825 companies
in the Medical Devices & Instruments industry
Industry Median: 3.22 vs XTER:SRT: 6.46

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-05), Sartorius AG's stock price is €223.00. Sartorius AG's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €48.69. Therefore, Sartorius AG's PS Ratio for today is 4.58.


Sartorius AG EV-to-Revenue Historical Data

The historical data trend for Sartorius AG's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG EV-to-Revenue Chart

Sartorius AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.25 11.04 10.53 6.20 6.99

Sartorius AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.11 5.43 6.59 6.99 7.23

Competitive Comparison of Sartorius AG's EV-to-Revenue

For the Medical Instruments & Supplies subindustry, Sartorius AG's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius AG's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sartorius AG's EV-to-Revenue falls into.



Sartorius AG EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Sartorius AG's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=21406.908/3312.1
=6.46

Sartorius AG's current Enterprise Value is €21,407 Mil.
Sartorius AG's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €3,312 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sartorius AG  (XTER:SRT) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Sartorius AG's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=223.00/48.685
=4.58

Sartorius AG's share price for today is €223.00.
Sartorius AG's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €48.69.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sartorius AG EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sartorius AG's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sartorius AG (XTER:SRT) Business Description

Address
Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.